Julia Carrasco-Valiente
Sofia University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Julia Carrasco-Valiente.
International Journal of Urology | 2013
Francisco Jose Anglada‐Curado; Pablo Campos‐Hernández; Julia Carrasco-Valiente; Fernando Anaya‐Henares; Jose Luis Carazo‐Carazo; Jose Alvarez‐Kindelán; Juan Carlos Regueiro‐López; Maria José Requena-Tapia
To compare low versus high frequency for lithotripsy in the management of distal ureteral calculi.
Urology | 2010
Francisco Jose Anglada‐Curado; Jesús De Haro-Padilla; Julia Carrasco-Valiente; Jose Alvarez‐Kindelán; Jesús Ruiz-García; Maria José Requena-Tapia
Renal carcinoma may develop metachronous distant metastases without evidence of regional or local disease recurrence. These lesions may be misdiagnosed because of its benign-like appearance and lack of evidence of other disease spread.
Journal of Cellular and Molecular Medicine | 2018
Enrique Gómez-Gómez; Juan M. Jiménez-Vacas; Julia Carrasco-Valiente; Vicente Herrero-Aguayo; Ana M. Blanca-Pedregosa; Antonio J Leon-Gonzalez; José Valero-Rosa; José L. Fernández-Rueda; Teresa González-Serrano; Jose Lopez-Miranda; Manuel D. Gahete; Justo P. Castaño; María J. Requena-Tapia; Raúl M. Luque
Abstract Early detection of PCa faces severe limitations as PSA displays poor‐specificity/sensitivity. As we recently demonstrated that plasma ghrelin O‐acyltransferase (GOAT)‐enzyme is significantly elevated in PCa‐patients compared with healthy‐controls, using a limited patients‐cohort, we aimed to further explore the potential of GOAT to improve PCa diagnosis using an ample patients‐cohort (n = 312) and defining subgroups (i.e. significant PCa/metastatic patients, etc.) that could benefit from this biomarker. Plasma GOAT‐levels were evaluated by ELISA in patients with (n = 183) and without (n = 129) PCa. Gleason Score ≥ 7 was considered clinically significant PCa. GOAT‐levels were higher in PCa patients vs control patients, and in those with significant PCa vs non‐significant PCa. GOAT‐levels association with the diagnoses of significant PCa was independent from traditional clinical variables (i.e. PSA/age/DRE). Remarkably, GOAT outperformed PSA in patients with PSA‐levels ranging 3‐20 ng/mL for the significant PCa diagnosis [GOAT‐AUC = 0.612 (0.531‐0.693) vs PSA‐AUC = 0.494 (0.407‐0.580)]. A panel of key variables including GOAT/age/DRE/testosterone also outperformed the same panel but with PSA [AUC = 0.720 (0.710‐0.730) vs AUC = 0.705 (0.695‐0.716), respectively]. Notably, GOAT‐levels could also represent a novel predictive biomarker of aggressiveness, as its levels are positively associated with Gleason Score and the presence of metastasis at the time of diagnoses. Altogether, our data reveal that GOAT‐levels can be used as a non‐invasive biomarker for significant PCa diagnosis in patients at risk of PCa (with PSA: 3‐20 ng/mL).
Cancer Letters | 2016
Daniel Hormaechea-Agulla; Enrique Gómez-Gómez; Alejandro Ibanez-Costa; Julia Carrasco-Valiente; Esther Rivero-Cortés; Fernando L-López; Sergio Pedraza-Arevalo; José Valero-Rosa; Rafael Sánchez-Sánchez; Rosa Ortega-Salas; María Moreno; Manuel D. Gahete; Jose Lopez-Miranda; Maria J. Requena; Justo P. Castaño; Raúl M. Luque
The FASEB Journal | 2017
Daniel Hormaechea-Agulla; Juan M. Jiménez-Vacas; Enrique Gómez-Gómez; Fernando L.-López; Julia Carrasco-Valiente; José Valero-Rosa; María Moreno; Rafael Sánchez-Sánchez; Rosa Ortega-Salas; Francisco Gracia-Navarro; Michael D. Culler; Alejandro Ibanez-Costa; Manuel D. Gahete; Maria J. Requena; Justo P. Castaño; Raúl M. Luque
Revista Internacional de Andrologia | 2014
Julia Carrasco-Valiente; Juan Pablo Campos-Hernández; Jesús Ruiz-García; Francisco Javier Márquez-López; Maria José Requena-Tapia; Rafael Prieto-Castro
Molecular Cancer | 2017
Daniel Hormaechea-Agulla; Manuel D. Gahete; Juan M. Jiménez-Vacas; Enrique Gómez-Gómez; Alejandro Ibanez-Costa; Fernando L-López; Esther Rivero-Cortés; André Sarmento-Cabral; José Valero-Rosa; Julia Carrasco-Valiente; Rafael Sánchez-Sánchez; Rosa Ortega-Salas; María Moreno; Natia Tsomaia; Steve M. Swanson; Michael D. Culler; Maria J. Requena; Justo P. Castaño; Raúl M. Luque
19th European Congress of Endocrinology | 2017
Juan M. Jiménez-Vacas; Manuel D. Gahete; Sergio Pedraza-Arevalo; Rio-Moreno Mercedes del; Daniel Hormaechea-Agulla; Enrique Gómez-Gómez; Julia Carrasco-Valiente; Mar Moreno Maria del; Requena-Tapia Maria Jose; Justo P. Castaño; Raúl M. Luque
European Urology Supplements | 2016
Gomez E. Gomez; S. Pedraza-Arévalo; Julia Carrasco-Valiente; Daniel Hormaechea-Agulla; Rosa J. Valero; Alejandro Ibanez-Costa; María Moreno; Manuel D. Gahete; J.P. Campos-Hernandez; Justo P. Castaño; M.J. Requena-Tapia; Raúl M. Luque
European Urology Supplements | 2016
Gomez E. Gomez; M.A. Fernández-Peralbo; Julia Carrasco-Valiente; M. Calderón-Santiago; J. Ruiz-García; F. Priego-Capote; Castro M.D. Luque De; M.J. Requena-Tapia